OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Tam Discusses the Side Effect Profile of Duvelisib in CLL

February 8th 2018

Constantine S. Tam, MD, associate professor, Peter MacCallum Cancer Centre, discusses the side effect profile of duvelisib in patients with chronic lymphocytic leukemia (CLL).

Dr. Carey Discusses Findings From the CALGB40502 Trial in TNBC

February 7th 2018

Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses findings from the CALGB 40502/NCCTG N063H trial in triple-negative breast cancer.

Dr. Morgan on Combinations With PARP Inhibitors in Prostate Cancer

February 7th 2018

Alicia Morgan, MD, Mather Hospital, discusses combinations with PARP inhibitors in prostate cancer.

Dr. Markman on Overall Survival as an Endpoint in Ovarian Cancer Trials

February 7th 2018

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses overall survival as an endpoint in ovarian cancer clinical trials.

Dr. Locke Discusses Long-Term Follow-Up of ZUMA-1 Trial for NHL

February 7th 2018

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant at Moffitt Cancer Center, and an assistant professor of Oncology at the University of South Florida, discusses long-term follow-up results of the ZUMA-1 trial for patients with non-Hodgkin lymphoma (NHL).

Dr. Kaplan Discusses Combinations With Rituximab for MCL

February 7th 2018

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, division of Hematology-Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses combinations with rituximab (Rituxan) for patients with mantle cell lymphoma (MCL).

Dr. Bustoros on Next-Generation Sequencing in Multiple Myeloma

February 7th 2018

Mark W. Bustoros, MD, Dana-Farber Cancer Institute, discusses the role of next-generation sequencing for patients with multiple myeloma.

Dr. Huang on the Widespread Adoption of Robotic Surgery for Bladder Surgery

February 7th 2018

William C. Huang, MD, associate professor, department of Urology, co-director, Robotics Program, Chief Urology Service, Tisch Hospital, NYU Langone Health, discusses misconceptions regarding robotic-assisted bladder surgery.

Dr. Smith on Acquired Resistance to Targeted Agents for AML

February 7th 2018

Catherine Smith, MD, assistant professor, Division of Hematology/Oncology, Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses patient acquired resistance in quizartinib (AC220) and gilteritinib (ASP2215) in acute myeloid leukemia (AML).

Dr. Crane on the Use of Proton Therapy and the MR-Linear Accelerator in GI Malignancies

February 7th 2018

Christopher Crane, MD, vice chair, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, discusses the emergence and success of new technologies in the treatment of patients with gastrointestinal (GI) malignancies.

Dr. Stinchcombe Discusses the PACIFIC Trial for NSCLC

February 7th 2018

Thomas E. Stinchcombe, MD, professor of medicine, Duke Cancer Institute, discusses the PACIFIC trial for patients with non–small cell lung cancer (NSCLC).

Dr. Hammers on the Future of Immunotherapy in RCC

February 7th 2018

Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the future of immunotherapy for patients with renal cell carcinoma (RCC).

Dr. Rugo on Ongoing Trials in HER2+ Breast Cancer

February 7th 2018

Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses ongoing trials for patients with HER2-positive breast cancer.

Dr. Erhunmwunsee on Factors of Disparity in Lung Cancer Treatment

February 6th 2018

Loretta Erhunmwunsee, MD, thoracic surgeon, assistant professor of surgery, City of Hope, discusses the factors that contribute to disparities in the treatment of patients with lung cancer.

Dr. Voss on the Case for Neoadjuvant Treatment in Kidney Cancer

February 6th 2018

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, explains the case for neoadjuvant therapy in the treatment of kidney cancer.

Dr. Bekaii-Saab Discusses the ReDOS Study in Metastatic CRC

February 6th 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the phase II regorafenib (Stivarga) dose optimization study (ReDOS) in metastatic colorectal cancer.

Dr. Wong on Anti-Amyloid Fibril Treatments in AL Amyloidosis

February 6th 2018

Sandy Wong, MD, assistant professor, University of California, San Francisco School of Medicine, discusses anti-amyloid fibril treatments, a class of agents that have yet to receive FDA approval in the treatment of patients with immunoglobulin light chain amyloidosis (AL amyloidosis).

Dr. Skarbink on Unmet Needs for High-Risk Hematologic Malignancies

February 6th 2018

Alan Skarbnik, MD, staff physician, department of Bone Marrow Transplant, department of Lymphoma, John Theurer Cancer Center, discusses unmet needs for patients with high-risk hematologic malignancies.

Dr. Pishvaian on Molecular Alteration in Pancreatic Cancer

February 6th 2018

Michael Pishvaian, MD, PhD, director, Phase I Clinical Program, co-director of the Ruesch Center Pancreatic Cancer Program Medical Oncology, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown University Lombardi Comprehensive Cancer Center, discusses the background of a study investigating molecular alterations for patients with pancreatic cancer.

Dr. Taylor on the Future of Treatments for Endometrial Cancer

February 6th 2018

Alexandra Taylor, MD, consultant, clinical oncology, The Royal Marsden Hospital, discusses the future of treatments for patients with endometrial cancer.